Introduction
============

All mature blood cells are derived from hematopoietic stem cells, and this process is known as hematopoiesis. In a healthy adult, 10^11^-10^12^ new blood cells are produced daily in order to maintain a steady state in the peripheral circulation ([@b1-ol-0-0-8050]). Granulocytes are a class of white blood cells marked with the presence of granules in their cytoplasm, which serve important roles in the innate immune system and are involved in chemotaxis, phagocytosis and bactericidal action ([@b2-ol-0-0-8050]). Monocytes are the largest of all leukocytes, characterized by a granulated cytoplasm. Monocytes also have multiple roles in immune function, including replenishing resident macrophages and differentiating into macrophages and dendritic cells to elicit an immune response ([@b3-ol-0-0-8050],[@b4-ol-0-0-8050]). Granulocytes and monocytes are derived from the common myeloid progenitors. Granulocytic and macrophage-like differentiation and maturation are important components of normal hematopoiesis ([@b5-ol-0-0-8050]). Blocking myeloid differentiation results in acute myeloid leukemia (AML). AML is characterized by the reduced production of functional blood cells and overproduction and accumulation of immature white blood cells. The symptoms of AML include fatigue, shortness of breath, easy bruising and bleeding and an increased risk of infection ([@b6-ol-0-0-8050]). AML is the most common type of acute leukemia affecting adults, and the incidence of AML increases with age ([@b7-ol-0-0-8050],[@b8-ol-0-0-8050]). The French-American-British (FAB) classifies AML into eight subtypes (M0-M7) according to cell morphology and maturation ([@b9-ol-0-0-8050]). From M1 to M5, AML cases involving granulocytic and macrophage-like differentiation blockage account for 85% of adult AML cases ([@b9-ol-0-0-8050],[@b10-ol-0-0-8050]). Granulocytic and monocytic differentiation is regulated by multiple factors, including key transcriptional factors (PU.1, CCAAT/enhancer-binding protein α, interferon regulatory factor 8, TAL bHLH transcription factor 1 and runt-related transcription factor 1) ([@b11-ol-0-0-8050]), cytokines \[granulocyte colony-stimulating factor (CSF), macrophage-CSF and interleukin-3\] ([@b12-ol-0-0-8050]) and non-coding RNAs ([@b13-ol-0-0-8050]).

MicroRNAs (miRNA) are a class of small non-coding RNAs, which regulate gene expression post-transcriptionally through degradation of mRNA or inhibition of mRNA translation. miRNAs have been reported to be involved in numerous physiological and pathological biological processes ([@b14-ol-0-0-8050]). A number of miRNAs have been indicated to be involved in myeloid differentiation and AML progression, including the miR-223, miR-142-3p, miR-29 and miR-181 families ([@b15-ol-0-0-8050]--[@b17-ol-0-0-8050]). The miR-10 family consists of two members, miR-10a and miR-10b, which are located at chromosome 17 and 2, respectively ([@b18-ol-0-0-8050]). Accumulating evidence suggests that miR-10a/b may act as novel oncogenes in various types of human cancer, including metastatic breast cancer, pancreatic cancer, esophageal cancer, hepatocellular carcinoma, nasopharyngeal carcinoma and colorectal cancer ([@b19-ol-0-0-8050]--[@b28-ol-0-0-8050]). These findings suggest that miR-10a and miR-10b are strongly expressed in highly metastatic cancer and serve important roles in cancer metastasis. miR-10a and miR-10b have also been reported to be upregulated in nucleophosmin (NPM1)-mutated AMLs ([@b29-ol-0-0-8050],[@b30-ol-0-0-8050]). However, the regulatory role of miR-10a/b in AML remains unknown.

In the present study, the expression of miR-10a and miR-10b was examined in a number of AML cases and healthy donor controls. It was revealed that the expression of miR-10a and miR-10b was increased in AML cases compared with healthy controls, particularly in M1, M2 and M3 subtypes. Additionally, the levels of miR-10a and miR-10b were upregulated in AML patients with mutated NPM1, and also AML patients with t(8;21) and t(9;11), compared with the normal controls. Furthermore, the roles of miR-10a and miR-10b in regulating granulocytic and monocytic differentiation and AML progression were investigated. The results indicated that miR-10a and miR-10b were able to promote the proliferation of human promyelocytic leukemia HL-60 cells, while suppressing the granulocytic and monocytic differentiation of HL-60 cells. These findings suggested that abnormal high expression of miR-10a and miR-10b may result in unlimited proliferation of immature blood progenitors and the repression of mature blood cell differentiation and maturation, thus leading to the occurrence of AML. Therefore, miR-10a and miR10b may be developed as new therapeutic targets of AML.

Materials and methods
=====================

### Human samples

The peripheral blood samples of patients with AML (89 patients) and normal volunteers (65 patients) were obtained from The First Affiliated Hospital of Wenzhou Medical University (Nanbaixiang, Ouhai, Wenzhou, Zhejiang) from January to December 2015. The gender ratio of the patients and controls was approximately 1:1 and aged between 2--60 years old. Written informed consent to perform the biological studies was obtained from all examined patients. The present study was approved by the Ethics Committees of The First Affiliated Hospital of Wenzhou Medical University. Mononuclear cells were isolated from the peripheral blood samples of patients with AML and normal volunteers using lymphocyte separation medium (Lonza Walkersville, Inc., Walkersville, MD, USA). The peripheral blood samples were first diluted with phosphate-buffered saline (PBS; 1:4) and then plated on the lymphocyte separation medium. The middle layer of mononuclear cells was collected following centrifugation at 1,000 × g for 30 min at room temperature.

### Cell culture and transfections

The human leukemia HL-60 cells (ATCC, Manassas, VA, USA) were grown in Iscove\'s modified Dulbecco\'s medium (Invitrogen; Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.,), 50 U/ml penicillin and 50 µg/ml streptomycin (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) at 37°C in a 5% CO~2~ cell culture incubator. All-trans-retinoic acid (ATRA; 50 ng/ml; Sigma-Aldrich; Merck KGaA) and phorbol myristate acetate (PMA; 2 µM; Sigma-Aldrich; Merck KGaA) were used to induce HL-60 cells to undergo granulocytic and monocytic differentiation. miR-10a mimics, miR-10b mimics and scramble control were obtained from Dharmacon (GE Healthcare Life Sciences, Little Chalfont, UK) and transfected with DharmFECT1 (Dharmacon; GE Healthcare Life Sciences) into HL-60 cells at a final concentration of 50 nM.

### May-Grünwald Giemsa staining

HL-60 cells undergoing granulocytic and monocytic differentiation were harvested at indicated time. Cells were smeared on glass slides, fixed in 100% methanol for 10 min at room temperature, then stained with May-Grünwald/Giemsa (cat. no. BA-4017; BaSO Diagnostics Inc., Zhuhai, China) for 5 min at room temperature, and analyzed at ×400 magnification under an inverted microscope (Nikon TE2000; Nikon Corporation, Tokyo, Japan) equipped with a digital camera.

### RNA extraction, cDNA synthesis and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assays

Total RNA was extracted from cultured cells and mononuclear cells isolated from peripheral blood using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. cDNA was synthesized using high-capacity cDNA reverse transcription Kit (Thermo Fisher Scientific, Inc.) from 1--5 µg of total RNA. For detection of microRNA expression, a stem-loop RT primer was used for the reverse transcription of miR-10a/b. For detection of mRNA expression, oligodT primer was used for the reverse transcription of mRNA. RT-qPCR using SYBR^®^ Green qPCR Master Mix (Takara Bio, Inc., Otsu, Japan) was performed in a Bio-Rad CFX96 real-time PCR System (Bio-Rad Laboratories, Inc., CA, USA) according to the manufacturer\'s protocols. The PCR conditions were as follows: 95°C for 30 sec, followed by 40 cycles of 95°C for 5 sec and 60°C for 34 sec. The data were normalized using the endogenous U6 small nuclear RNA and GAPDH. The 2^−ΔΔCq^ method ([@b31-ol-0-0-8050]) was used in the analysis of PCR data. Primer sequences are presented in [Table I](#tI-ol-0-0-8050){ref-type="table"}.

### Flow cytometry and fluorescence-activated cell sorting analysis (FACS)

HL-60 cells were harvested at 48 h after transfection and were washed twice at 4°C in PBS containing 0.5% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.). ATRA- or PMA-induced HL-60 cells were incubated with phycoerythrin-conjugated cluster of differentiation molecule 11B (CD11b) antibody (CD11b04-4; eBioscience; Thermo Fisher Scientific, Inc.) or fluorescein isothiocyanate-conjugated anti-cluster of differentiation CD14 antibody (11-0141-82; eBioscience; Thermo Fisher Scientific, Inc.) at 1:100 dilution for 30 min at room temperature. Flow cytometry was performed using a C6 flow cytometer instrument (BD Biosciences, Franklin Lakes, NJ, USA) and subsequently analyzed with CFlow Sampler Analysis 1.0.208.2 (BD Biosciences).

### Cell proliferation assay

To measure the effect of miRNA mimics on proliferation of HL-60 cells, the cells were incubated in 10% cell counting kit-8 solution (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) and diluted in normal culture medium at 37°C until color change has taken place. Proliferation rates were determined on day 1, 2, 3 and 4 post-transfection, and quantification was performed on a microtiter plate reader (Spectra Rainbow, Tecan Trading AG, Männedorf, Switzerland) at OD450 nm according to the manufacturer\'s protocol.

### Statistical analysis

Comparisons between multiple groups were analyzed using one-way analysis of variance and the least significant difference post hoc test using GraphPad Prism 5 v5.01 (Graph Pad Software, Inc., La Jolla, CA, USA). Comparisons between two groups were evaluated by independent sample t-test (two-tailed). P≤0.05 was considered to indicate a statistically significant difference. Data are presented as the mean ± standard deviation.

Results
=======

### miR-10a and miR-10b are significantly increased in patients with AML

To accurately examine the expression of miR-10a and miR-10b in AML, TaqMan quantitative PCR was used to detect the levels of miR-10a and miR-10b in peripheral blood mononuclear cells (PBMNCs) derived from 89 patients with AML and 65 healthy donors ([Fig. 1](#f1-ol-0-0-8050){ref-type="fig"}).

Compared with the normal controls, the expression of miR-10a increased significantly in AML cases (P\<0.001; [Fig. 1A](#f1-ol-0-0-8050){ref-type="fig"}). These AML cases that were analyzed included major FAB subtypes from M1 to M5, including 13 cases of M1, 28 cases of M2, 21 cases of M3, 10 cases of M4 and 17 cases of M5. The expression level of miR-10a was also compared in the different AML subtypes, and it was indicated that the expression of miR-10a in M1, M2 and M3 AML subtypes was increased compared with M4, M5 and normal controls. The expression of miR-10a in M4 and M5 subtypes was also higher compared with normal controls, but this difference was not statistically significant ([Fig. 1B](#f1-ol-0-0-8050){ref-type="fig"}).

In addition, the expression of miR-10a and miR-10b based on cytogenetic karyotypes was also compared in 57 patients with AML, whose cytogenetic karyotype and gene mutation had been detected. The results showed that miR-10a was significantly upregulated in AML patients with t(8;21) and t(9;11), but not in patients with AML with t(15;17) and t(10;16) when compared with the normal controls ([Fig. 1C](#f1-ol-0-0-8050){ref-type="fig"}). In addition, the expression level of miR-10a was also upregulated in patients with NPM1-mutated AML compared with normal controls, and patients with AML and wild-type NPM1 ([Fig. 1D](#f1-ol-0-0-8050){ref-type="fig"}), which was consistent with previous studies ([@b29-ol-0-0-8050],[@b30-ol-0-0-8050],[@b32-ol-0-0-8050]).

Similar to miR-10a expression, the expression of miR-10b also increased significantly in AML cases compared with the normal controls (P\<0.001; [Fig. 1E](#f1-ol-0-0-8050){ref-type="fig"}). The expression of miR-10b in M1, M2 and M3 AML subtypes was higher compared with the expression in M4, M5 and normal controls ([Fig. 1F](#f1-ol-0-0-8050){ref-type="fig"}). Additionally, the expression in M4 and M5 AML subtypes was also a little but not significant higher compared with the expression in normal controls ([Fig. 1F](#f1-ol-0-0-8050){ref-type="fig"}). The expression level of miR-10b expression was increased in patients with AML with t(8;21) and t(9;11) compared with the expression in normal controls ([Fig. 1G](#f1-ol-0-0-8050){ref-type="fig"}). Additionally, the level of miR-10b was significantly upregulated in patients with NPM1-mutated AML compared with normal controls, and patients with AML and wild-type NPM1 ([Fig. 1H](#f1-ol-0-0-8050){ref-type="fig"}). These results indicated the involvement of miR-10a and miR-10b in leukemogenesis.

### miR-10a and miR-10b are gradually decreased during granulocytic and monocytic differentiation of human leukemia cells

To examine the possible role of miR-10a and miR-10b in granulocytic and monocytic differentiation and leukemogenesis, the expression level of the two miRNAs was detected during granulocytic and monocytic differentiation of human leukemia HL-60 cells. HL-60 was induced to undergo granulocytic or monocytic differentiation using ATRA or PMA, respectively, as previously reported ([@b33-ol-0-0-8050]). As Giemsa staining shown, more mature granulocytic cells show polylobular nuclei, more mature monocytes show bluish-gray cytoplasm and a saddle-shaped nucleus ([Fig. 2A and B](#f2-ol-0-0-8050){ref-type="fig"}) qPCR was used to detect the level of miR-10a and miR-10b expression at 12, 24, 48 and 72 h post-induction. The results showed that miR-10a/b decreased significantly during ATRA-induced granulocytic differentiation ([Fig. 2C](#f2-ol-0-0-8050){ref-type="fig"}) and PMA-induced monocytic differentiation ([Fig. 2D](#f2-ol-0-0-8050){ref-type="fig"}). These findings suggested that miR-10a and miR-10b may perform critical roles in granulocytic/monocytic differentiation.

### miR-10a promotes proliferation of human leukemia cells and inhibits differentiation of human leukemia cells to granulocytes and monocytes

Given the decrease in miR-10a and miR-10b expression during granulocytic/monocytic differentiation of HL-60 cells, it was questioned whether miR-10a and miR-10b regulate granulocytic/monocytic differentiation or proliferation of leukemia cells. miR-10a mimics were transfected into HL-60 cells. Cell growth rate and differentiation were then examined. miR-10a was successfully overexpressed in HL-60 cells as confirmed by qPCR ([Fig. 3A](#f3-ol-0-0-8050){ref-type="fig"}). Cell proliferation rates were determined at days 1, 2, 3 and 4 post-transfection, and overexpression of miR-10a in HL-60 cells was observed to be able to significantly promote the proliferation of leukemia cells compared with the scramble control ([Fig. 3B](#f3-ol-0-0-8050){ref-type="fig"}).

In addition, the effect of miR-10a on the ability of leukemia cells to differentiate into granulocyte and monocytes was investigated. Transfected HL-60 cells were induced to undergo granulocytic/monocytic differentiation, and the expression of CD11b and CSF3 receptor (CSF3R) were used to estimate the progression of granulocytic differentiation, while the expression of CD14 and CSF1 receptor (CSF1R) were used to estimate the progression of monocytic differentiation. FACS analysis of CD11b and CD14 was also used to examine the granulocytic/monocytic differentiation of HL-60 cells. The results demonstrated that ectopic expression of miR-10a was able to suppress the upregulation of CD11b and CSF3R during ATRA-induced granulocytic differentiation ([Fig. 3C](#f3-ol-0-0-8050){ref-type="fig"}) and also was able to decrease the percentage of CD11b-positive cells ([Fig. 3D](#f3-ol-0-0-8050){ref-type="fig"}). Ectopic expression of miR-10a also significantly inhibited the upregulation of CD14 and CSF1R during PMA-induced monocytic differentiation ([Fig. 3E](#f3-ol-0-0-8050){ref-type="fig"}) and decreased the percentage of CD14-positive cells ([Fig. 3F](#f3-ol-0-0-8050){ref-type="fig"}), indicating that miR-10a performs a negative role in granulocytic/monocytic differentiation of HL-60 cells.

### miR-10b promotes cell proliferation and suppresses granulocytic and monocytic differentiation

The role of miR-10b in regulating granulocytic/monocytic differentiation and cell proliferation of leukemia cells was also detected, in the same way as miR-10a. miR-10b was successfully overexpressed in HL-60 cells as confirmed by qPCR ([Fig. 4A](#f4-ol-0-0-8050){ref-type="fig"}). Cell proliferation rates were determined at days 1, 2, 3 and 4 post-transfection, and ectopic expression of miR-10b was observed to promote the proliferation of leukemia cells ([Fig. 4B](#f4-ol-0-0-8050){ref-type="fig"}). In addition, it was revealed that overexpression of miR-10b suppressed the upregulation of CD11b and CSF3R during ATRA-induced granulocytic differentiation ([Fig. 4C](#f4-ol-0-0-8050){ref-type="fig"}) and also decreased the percentage of CD11b-positive cells ([Fig. 4D](#f4-ol-0-0-8050){ref-type="fig"}). Furthermore, the overexpression of miR-10b also significantly inhibited the upregulation of CD14 and CSF1R during PMA-induced monocytic differentiation ([Fig. 4E](#f4-ol-0-0-8050){ref-type="fig"}) and decreased the percentage of CD14-positive cells ([Fig. 4F](#f4-ol-0-0-8050){ref-type="fig"}), indicating that miR-10b has a negative role in granulocytic/monocytic differentiation of HL-60 cells.

Discussion
==========

Several studies have investigated the association between abnormal miR-10a/b expression and the risk of developing various types of cancer, but the results are inconsistent ([@b19-ol-0-0-8050],[@b21-ol-0-0-8050],[@b23-ol-0-0-8050],[@b26-ol-0-0-8050]). Accumulating evidence suggests that miR-10a and miR-10b may behave as novel oncogenes in human cancer ([@b26-ol-0-0-8050]--[@b28-ol-0-0-8050],[@b34-ol-0-0-8050],[@b35-ol-0-0-8050]). The detection of upregulation of miR-10a expression may serve as potential biomarkers of aggressive progression and poor prognosis in cervical cancer ([@b34-ol-0-0-8050]) miR-10b has also been reported to promote cell invasion by targeting homeobox (HOX) D10 in gastric cancer ([@b35-ol-0-0-8050]). However, debate exists on whether miR-10a/b acts as a tumor suppressor or oncogene in human cancer ([@b34-ol-0-0-8050]--[@b37-ol-0-0-8050]). Kim *et al* ([@b36-ol-0-0-8050]) reported that miR-10b may act as a tumor suppressive gene in gastric carcinogenesis. The loss of miR-10a was also reported to activate lactoperoxidase to induce intestinal neoplasia through cooperating with activated Wnt signaling in female mice ([@b37-ol-0-0-8050]). However, the aberrant expression and the potential role of miR-10a/b in AML are largely unknown, with the exception that miR-10a was reported to be expressed at high levels in NPM1-mutated AML ([@b38-ol-0-0-8050]) and that the level of serum miR-10a was also investigated as a prognostic biomarker for AML ([@b39-ol-0-0-8050]).

In the present study, the expression of miR-10a and miR-10b was examined in a number of patients with AML and healthy controls. Additionally, the potential application of the levels of miR-10a and miR-10b expression in AML diagnosis was investigated. The results indicated that miR-10a and miR-10b were significantly upregulated in AML samples. The upregulation of miR-10a and miR-10b in AML indicated that miR-10a/b may serve as potential biomarkers for diagnosis of AML. Several innate properties of miRNAs make them attractive as potential biomarkers. miRNAs are small and stable against degradation and can be detected easily by specific and sensitive RT-qPCR in small amount samples. In addition, miRNAs are also detectable in bodily fluids, including serum, plasma, saliva, urine and tears ([@b40-ol-0-0-8050],[@b41-ol-0-0-8050]). Furthermore, expression profiles of miRNAs in the plasma and/or serum of cancer patients may reflect the change in miRNA expression in tumor cells ([@b42-ol-0-0-8050]). Circulating miRNAs may be a novel class of non-invasive biomarkers for cancer diagnostic and prognostic information ([@b43-ol-0-0-8050],[@b44-ol-0-0-8050]). The differential expression of miR-10a/b in different AML subtypes should be validated in more clinical samples to develop a novel method for subtyping AML according to miRNA expression.

In addition, to the best of our knowledge, there has not been any study that investigated the role of miR-10a and miR-10b in the progression of AML. The present study revealed that the exogenous expression of miR-10a and miR-10b in HL-60 cells decreased the maturation of HL-60 cells to granulocytes and monocytes, as well as the expression of the granulocytic and monocytic differentiation markers. The overexpression of miR-10a and miR-10b was able to promote the proliferation of leukemia cells. It was hypothesized that the abnormal upregulation of miR-10a/b in blood progenitor cells would result in the overproduction and accumulation of immature white blood cells, as well as the inhibition of granulocyte and monocyte maturation, which results in leukemogenesis. The oncogenic role of miR-10a/b in the progression of AML will be investigated in animal models.

In humans, miR-10 is co-expressed with a set of Hox genes and has been demonstrated to regulate the translation of Hox transcripts ([@b45-ol-0-0-8050],[@b46-ol-0-0-8050]). Hox genes perform crucial roles during development and are also involved in the tumorigenesis of various types of cancer ([@b46-ol-0-0-8050]). HOXA1 has been identified as a direct target of miR-10a in gastric cancer, megakaryocytopoiesis and pancreatic cancer ([@b47-ol-0-0-8050]). The miR-10 family has also been reported to facilitate cancer by regulating ribosome biogenesis and consequently global protein production ([@b48-ol-0-0-8050]). Therefore, it was hypothesized that miR-10a and miR-10b modulate granulocytic/monocytic differentiation and AML carcinogenesis through regulating Hox gene expression or ribosome biogenesis. The possible mechanism by which miR-10a and miR-10b regulate granulocytic and monocytic differentiation and AML carcinogenesis requires additional investigation.
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![Levels of miR-10a and miR-10b expression are significantly increased in AML cases. (A) The expression level of miR-10a in PBMNCs derived from 89 patients with AML and 65 healthy donors detected by TaqMan quantitative polymerase chain reaction. (B) The expression level of miR-10a in different AML subtypes, from M1 to M5. (C) The expression level of miR-10a in different WHO subtypes of AML patients compared with the normal controls. (D) The expression level of miR-10a in AML patients with mutated and wild-type NPM1 compared with the normal controls. (E) The expression level of miR-10b in PBMNCs derived from 89 AML patients and 65 healthy donors. (F) The expression level of miR-10b in different AML subtypes, from M1 to M5. (G) The expression level of miR-10b in different WHO subtypes of AML patients compared with the normal controls. (H) The expression level of miR-10b in AML patients with mutated and wild-type NPM1 compared with the normal controls. \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001, \*\*\*\*P\<0.0001; ns, not significant. AML, acute myeloid leukemia; miR, microRNA; NPM1, nucleophosmin; PBMNC, peripheral blood mononuclear cell; WHO, World Health Organization; NPM1+, NPM1 mutated; NPM1-, wild-type NPM1.](ol-15-04-5611-g00){#f1-ol-0-0-8050}

![Decreased miR-10a/b expression during granulocytic and monocytic differentiation of HL-60 cells. (A and B) May-Grünwald Giemsa staining of HL-60 cells that were induced by ATRA or PMA for 0, 24 and 72 h, respectively. The differentiated macrophages and monocytes were indicated with arrows. (C) Changes in expression level of miR-10a and miR-10b during ATRA-induced HL-60 granulocytic differentiation at 12, 24, 48 and 72 h post-induction. (D) Changes in the level of (C) miR-10a and (D) miR-10b expression during PMA-induced monocytic differentiation. Data are presented as the mean ± standard deviation. miR, microRNA; ATRA, all-trans-retinoic acid; PMA, phorbol myristate acetate.](ol-15-04-5611-g01){#f2-ol-0-0-8050}

![miR-10a promotes the proliferation of HL-60 cells, while inhibits the differentiation of HL-60 cells to granulocytes and monocytes. (A) miR-10a is overexpressed in HL-60 cells as confirmed by quantitative polymerase chain reaction. (B) The growth of HL-60 cells at day 0, 1, 2, 3 and 4 post-transfection, which was detected by Cell Counting Kit-8 assay. (C) The expression level of granulocytic marker CD11b and CSF3R in untreated and ATRA-treated (duration, 48 h) cells that overexpress miR-10a. (D) CD11b FACS analysis showed that overexpression of miR-10a was able to delay ATRA-induced granulocytic differentiation of HL-60 cells. The percentage of CD11b-positive cells was calculated using the black traces referring to cells stained with CD11b antibody against the red traces referring to the same cells not stained with CD11b antibody. (E) The relative expression of monocytic marker CD14 and CSF1R in untreated and PMA-treated (duration, 48 h) cells that overexpress miR-10a. (F) CD14 FACS analysis showed that overexpression of miR-10a delayed PMA-induced monocytic differentiation of HL-60 cells. The percentage of CD14-positive cells was calculated in the same way. Data are presented as the mean ± standard deviation (n=3). All the comparisons are made between scramble and miR-10a groups. \*P\<0.05; \*\*P\<0.01; \*\*\*P\<0.001. miR, microRNA; CSF3R, colony-stimulating factor 3 receptor; ATRA, all-trans-retinoic acid; PMA, phorbol myristate acetate; CD, cluster of differentiation; CSF1R, colony-stimulating factor 1 receptor; FACS, fluorescence-activated cell sorting.](ol-15-04-5611-g02){#f3-ol-0-0-8050}

![miR-10b promotes the proliferation of HL-60 cells, while inhibits the differentiation of HL-60 cells to granulocytes and monocytes. (A) The overexpression of miR-10b in HL-60 cells as confirmed by quantitative polymerase chain reaction. (B) The growth of HL-60 cells at day 0, 1, 2, 3 and 4 post-transfection as detected by Cell Counting Kit-8 assay. (C) The expression level of granulocytic marker CD11b and CSF3R in untreated and ATRA-treated (duration, 48 h) cells that overexpress miR-10b. (D) CD11b FACS analysis showed that enforced expression of miR-10b delayed ATRA-induced granulocytic differentiation of HL-60 cells. (E) The relative expression of monocytic marker CD14 and CSF1R in untreated and PMA-treated (duration, 48 h) cells that overexpress miR-10b. (F) CD14 FACS analysis showed that enforced expression of miR-10b delayed PMA-induced monocytic differentiation of HL-60 cells. Data are presented as the mean ± standard deviation (n=3); \*P\<0.05; \*\*P\<0.01; \*\*\*P\<0.001. All the comparisons are made between scramble and miR-10a groups. miR, microRNA; CSF3R, colony-stimulating factor 3 receptor; CD, cluster of differentiation; CSF1R, colony-stimulating factor 1 receptor; ATRA, al-trans-retinoic acid; PMA, phorbol myristate acetate; FACS, fluorescence-activated cell sorting.](ol-15-04-5611-g03){#f4-ol-0-0-8050}

###### 

Sequences of primers used in reverse transcription-quantitative polymerase chain reaction.

  Primer            Sequence (5′-3′)
  ----------------- ------------------------------
  miR-10a-RT        GTCGTATCCAGTGCAGGGTCCGAGG
                    TATTCGCACTGGATACGACCACAAAT
  miR-10b-RT        GTCGTATCCAGTGCAGGGTCCGAGG
                    TATTCGCACTGGATACGCACAAATT
  miR-10a-forward   GCGC TACCCTGTAGATCCG
  miR-10a-reverse   GTGCTACCCTGTAGAAC
  miR-10b-forward   AGCTGTTCAGTGCACTACAGA
  miR-10b-reverse   GTGCTACCCTGTAGAAC
  miR-10a-probe     FAM-CCTGTAGATCCGAATTTG-MGB
  miR-10b-probe     FAM-CCTGTAGAACCGAATTTG-MGB
  U6-RT             AAAATATGGAACGCTTCACGAATTTG
  U6-forward        CTCGCTTCGGCAGCACATATACT
  U6-reverse        ACGCTTCACGAATTTGCGTGTC
  U6-probe          FAM-CCATGCTAATCTTCTCTGTA-MGB
  CD14-forward      GACCTAAAGATAACCGGCACC
  CD14-reverse      GCAATGCTCAGTACCTTGAGG
  CD11b-forward     CAGACAGGAAGTAGCAGCTCCT
  CD11b-reverse     CTGGTCATGTTGATGAAGGTGCT
  GAPDH-forward     TCAACGACCACTTTGTCAAGCTCA
  GAPDH-reverse     GCTGGTGGTCCAGGGGTCTTACT
  CSF1R-forward     GGGAATCCCAGTGATAGAGCC
  CSF1R-reverse     TTGGAAGGTAGCGTTGTTGGT
  CSF3R-forward     TCAAGTTGGTGCTATGGCAAGG
  CSF3R-reverse     GCTCCCAGTCTCCACAGAATC

CD, cluster of differentiation; CSF1R, colony-stimulating factor 1 receptor; CSF3R, colony stimulating factor 3 receptor; MGB, minor groove binder; FAM, fluorescein; RT, reverse transcription.
